Carthera sits at the interface of focused ultrasound, neuro-oncology, and CNS drug delivery infrastructure. Its SonoCloud platform is differentiated by an implantable BBB-opening approach and a registrational glioblastoma trial, giving it a more clinically advanced profile than most ultrasound delivery platforms.